Nek­tar says Eli Lil­ly mis­cal­cu­lat­ed da­ta in eczema tri­al be­fore break­ing off rezpeg part­ner­ship

Nek­tar Ther­a­peu­tics said its for­mer part­ner Eli Lil­ly had pre­sent­ed “er­ro­neous da­ta” for its atopic der­mati­tis drug be­fore break­ing off a $400 mil­lion al­liance. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER